The impact of cause of mismatch repair deficiency and other molecular markers on clinical outcomes with the use of durvalumab in advanced endometrial cancer in the phase 2 PHAEDRA trial (ANZGOG1601).

Authors

null

Daniel D. Buchanan

University of Melbourne, Parkville, VIC, Australia

Daniel D. Buchanan , Khalid Mahmood , Peter Georgeson , Romy Walker , Kristy Robledo , Michelle M. Cummins , Amanda B. Spurdle , Deborah S Smith , Eric Joo , Mark Clendenning , Julia Como , Susan Preston , Sonia Yip , John Andrews , Peey Sei Kok , Yeh Chen Lee , Martin R. Stockler , Linda R. Mileshkin , Yoland Catherine Antill

Organizations

University of Melbourne, Parkville, VIC, Australia, University of Melbourne, Parkville, Australia, NHMRC Clinical Trials Centre, The University of Sydney, Camperdown, NSW, Australia, QIMR Berghofer Medical Research Institute, Brisbane, Australia, Mater Pathology, University of Queensland, Brisbane, Australia, NHMRC Clinical Trials Centre, The University of Sydney, Sydney, Australia, ANZGOG, Camperdown, Australia, NHMRC Clinical Trials Centre, The University of Sydney, Camperdown, Australia, University Of Sydney, Camperdown, NSW, Australia, Department of Medical Oncology and the Sir Peter Maccallum Department of Oncology, Peter MacCallum Cancer Centre and the University of Melbourne, Melbourne, VIC, Australia, Cabrini Health, Malvern, Australia

Research Funding

Other
Australia and New Zealand Gynaecological Oncology Group

Background: In the single arm phase 2 PHAEDRA trial, MMR deficiency (dMMR) was predictive of response to durvalumab (1500mg IV Q4W), with an objective tumor response rate (OTR; defined by iRECIST) of 47% in dMMR compared with 3% in MMR-proficient (pMMR) advanced endometrial cancer (AEC). This substudy of the PHAEDRA trial investigates MMR molecular subtypes and other genomic tumor features and their correlation with treatment outcomes. Methods: Testing was performed to determine molecular subtypes of dMMR, including germline pathogenic variants in DNA MMR genes (Lynch syndrome), somatic biallelic MMR gene inactivation through somatic mutation and somatic hypermethylation of the MLH1 gene promoter. DNA from formalin-fixed paraffin-embedded tumor tissue and matched peripheral blood was available from 41/71 (25 dMMR, 16 pMMR) participants for testing on a custom capture-based 298-gene targeted panel (2.005Mb) including the MMR genes and key somatic AEC driver genes. The derived tumor genomic features included microsatellite instability (MSI), tumor mutational burden (TMB), COSMIC v.3.2 tumor mutational signatures and insertion/deletion (Indel) somatic mutation count. Results: Of the 71 patients recruited, 35 were dMMR and 36 were pMMR. Median follow-up was 44 vs 52 months in dMMR vs pMMR participants, respectively. The dMMR molecular subtypes were 4 (11.4%) Lynch syndrome, 4 (11.4%) somatic MMR mutation, 25 (71.4%) MLH1 methylated and 2 (5.7%) dMMR-uncategorised. The OTR rate was 100% (4/4; 95%CI 40-100%) for Lynch, 75% (3/4; 95%CI 22-99%) for somatic MMR mutations and 40% (10/25; 95%CI 22-61%) for MLH1 methylated groups. The median TMB (assessed in 41/71) was higher in those with a confirmed radiological response (37, IQR:26-50) vs non-responders (16, IQR:9-25; p < 0.001). Within the MLH1 methylated group, TMB was also higher in responders vs non-responders (40 v 21; p = 0.03). Somatic mutations in KRAS, PTEN, PIK3CA, ARID1A and TP53 were not associated with OTR rate. Conclusions: dMMR-MLH1 methylated AEC demonstrated greater heterogeneity in OTR to single agent durvalumab than the dMMR-Lynch and dMMR-somatic MMR mutation molecular subtypes. Higher TMB was seen in responders, and specifically within dMMR-MLH1 methylated responders, compared to non-responders. Clinical trial information: ANZGOG1601.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Abstract Details

Meeting

2023 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Gynecologic Cancer

Track

Gynecologic Cancer

Sub Track

Uterine Cancer

Clinical Trial Registration Number

ANZGOG1601

Citation

J Clin Oncol 41, 2023 (suppl 16; abstr 5604)

DOI

10.1200/JCO.2023.41.16_suppl.5604

Abstract #

5604

Poster Bd #

299

Abstract Disclosures

Similar Abstracts

Abstract

2024 ASCO Gastrointestinal Cancers Symposium

Prognostic effects of co-occurring TP53 and KRAS aberrations in patients with advanced biliary tract cancer.

First Author: Taro Shibuki